The Analysis Of Curative Effect On The Human Urinary Kallidinogenas And Ozagrel In Combined Treatment Of Acute Cerebral Infarction

Obiective:To investigate the efficacy and safety of Human Urinary Kallidinogenase in the treatment of acute cerebral infarction (ACI).Methods:80 patients with AC1 were divided into the treatment groups and control groups.39 patients in the treatment groups,41 patients in the control groups and it accords with the revised diagnostic of the Fourth National Conference on Cerebral Vascular of Chinese Medical Association in 1995. According to Oxford shire Community Stroke project (OCSP) classification:Partial anterior circulation infarction (PACI) 18, Lacunar infarction (LACI) 14, Posterior circulation infarction (POCI) 7. Divided by NIHSS severity of cerebral infarction:mild(o-6 points),moderate (7-15 points), severe(>16 points); 18 patients with mild, moderate 21 cases, no severe patients. Two groups in age, time of onset, classification of ischemic stroke, stroke severity, no significant difference on the NIHSS score (p> 0.05), it's comparable. All the patients were given sodium ozagrel therapy. Human Urinary Kallidinogenase was administrated to the patients in the treatment group for 14 days in addition to the sodium ozagrel therapy. All the patients have been evaluated by NIHSS at days 14 after the treatment. Side-effects were monitored at the same time. Results: Urinary Kallidinogenase treatment group overall, subgroups of the partial anterior circulation, posterior circulation infarction subgroup and moderate subgroups 14d, NIHSS score improvement than the corresponding control group (p<0.05), Lacunar infarction group and the mild sub-sub-group NIHSS score improvement after 14d and the corresponding control group was not statistically significant (p>0.05), Urinary Kallidinogenase group that were 56%,37% of the control group, showed no statistically significant difference (p>0.05). OCSP classification by further analysis, we found that effective from high to low were LACI>POCI>PACI regardless of Urinary Kallidinogenase group or control group. In the PACI group, Urinary Kallidinogenase group effective rate was 33%, significantly higher than the control group 5%(p<0.05), In POCI groups, although the Urinary Kallidinogenase effective rate was 71% higher than the 29%, but no statistically significant difference (p>0.05). In the LACI group, Urinary Kallidinogenase group was 79%, and it was the same as 80% of the control group. In the Treatment group,2 patients had adverse reactions (5.1%),1 case showed palpitation, sweating, diarrhea and The other one case showed ill performance, low blood pressure. Conclusion:Human Urinary Kamdinogenase may be effective and safety in treating mild to moderate cases with ACI.